Welcome to our dedicated page for Clearside Biomedical news (Ticker: CLSD), a resource for investors and traders seeking the latest updates and insights on Clearside Biomedical stock.
Clearside Biomedical, Inc. (symbol: CLSD) is a prominent clinical biopharmaceutical company based in Alpharetta, Georgia. Specializing in the development of pharmacological therapies, the company's primary focus is on treating blinding diseases of the eye through their innovative suprachoroidal space (SCS) technology.
Clearside Biomedical's cornerstone is their SCS Microinjector®, a proprietary device that facilitates a non-surgical, office-based procedure. This technology allows for targeted delivery of therapies directly to the macula, retina, or choroid, which could potentially preserve and enhance vision for patients suffering from severe eye conditions.
One of the company's significant achievements is the robust safety profile and encouraging efficacy data from multiple studies using the SCS Microinjector®. These findings have been featured in numerous oral and poster presentations, highlighting the potential of Clearside’s technology in ophthalmic therapeutics.
Clearside Biomedical continues to advance its pipeline of ophthalmic therapies, collaborating with various partners to bring innovative treatments to market. The company remains committed to improving the quality of life for individuals with vision-threatening diseases through groundbreaking research and development.
Recent Achievements:
- Clinical data utilizing Clearside’s suprachoroidal delivery technology featured in multiple presentations.
- Enhanced safety and efficacy data presented, showcasing the utility of the SCS Microinjector®.
Investors and media can reach out to Jenny Kobin and Remy Bernarda for more information at ir@clearsidebio.com or by calling (678) 430-8206.
Clearside Biomedical (Nasdaq: CLSD) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
1. Phase 2b ODYSSEY trial for CLS-AX in wet AMD on track with topline data expected in late Q3 2024.
2. Safety Review Committee recommended trial continuation with no serious adverse events observed.
3. Q2 2024 financial results: Revenue $90,000, net loss $7.6 million ($0.10 per share).
4. Cash position of $29.4 million, expected to fund operations into Q3 2025.
5. Progress in XIPERE commercialization and positive results from partner Arctic Vision's Phase 3 trial in China.
6. Advancements in suprachoroidal delivery platform and partnerships.
Clearside Biomedical (Nasdaq: CLSD), a biopharmaceutical company specializing in delivering therapies to the back of the eye through the suprachoroidal space (SCS®), has announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference. The company's management will present a corporate update available on demand from August 15, 2024, at 7:00 a.m. ET.
Additionally, Dr. Victor Chong, Chief Medical Officer, will take part in a panel discussion on the Evolving Therapeutic Landscape of AMD. Interested parties can access the live and archived webcast presentation through the Investors section of Clearside's website under Events and Presentations.
Clearside Biomedical (Nasdaq: CLSD), a biopharmaceutical company specializing in suprachoroidal space (SCS®) therapies for eye conditions, has announced its schedule for reporting second quarter 2024 financial results. The company will release its Q2 2024 financials on Monday, August 12, 2024, after the financial markets close. Notably, Clearside has opted not to hold a Q2 2024 conference call. Instead, they recently hosted a Suprachoroidal Delivery Key Opinion Leader Webinar on July 24, 2024, with a replay available on their website. The company plans to resume quarterly earnings conference calls starting with the third quarter 2024 financial results.
Clearside Biomedical (Nasdaq: CLSD) announced positive topline results from its partner Arctic Vision's Phase 3 clinical trial of ARCATUS® (ARVN001) for treating Uveitic Macular Edema (UME) in China. The trial met primary and secondary endpoints, showing significant visual acuity improvement and edema control. Key findings include:
- 38.5% of ARVN001-treated patients gained ≥15 ETDRS letters in vision vs 9.4% in the sham group
- Central subfield thickness reduction: 204.3 microns (ARVN001) vs 1.6 microns (sham)
- Mean BCVA gain: 9.6 letters at week 4, 12.2 letters at week 24
- No ocular serious adverse events reported
Additionally, Arctic Vision's new drug applications for ARCATUS have been accepted in Australia and Singapore, expanding the global opportunity for XIPERE®, Clearside's FDA-approved suprachoroidal space (SCS®) injection treatment.
Clearside Biomedical (Nasdaq: CLSD) has opened registration for a virtual key opinion leader (KOL) event on July 24, 2024, from 8:00 - 9:15 am ET. The webinar will focus on suprachoroidal drug delivery and its applications in retinal treatments, particularly for neovascular age-related macular degeneration (wet AMD). The event will feature presentations by renowned retinal experts:
1. Dr. David M. Brown, Director of Research at Retina Consultants Houston
2. Dr. Glenn C. Yiu, Professor of Ophthalmology at UC Davis
3. Dr. Victor Chong, Chief Medical Officer of Clearside Biomedical
The webinar will highlight the broad applicability and real-world experience with suprachoroidal drug delivery, ongoing clinical programs, and potential future development opportunities for Clearside.
Clearside Biomedical (Nasdaq: CLSD), renowned for its innovative suprachoroidal space (SCS®) therapies, has appointed Dr. Glenn C. Yiu to its Scientific Advisory Board (SAB). Dr. Yiu, Professor of Ophthalmology at UC Davis, brings extensive expertise in retinal diseases, gene therapy, and ocular imaging. He has pioneered significant advances, including using CRISPR-based genome editing for age-related macular degeneration (AMD) and developing microneedles for gene delivery. His role is poised to enhance Clearside's CLS-AX program and pipeline expansion. Dr. Yiu's appointment underlines Clearside's commitment to advancing retinal disease treatments through cutting-edge research and innovation.
Clearside Biomedical (Nasdaq: CLSD) will host a virtual key opinion leader (KOL) event on Wednesday, July 24, 2024, from 8:00 to 9:15 am ET. The event will focus on the use and versatility of suprachoroidal drug delivery, especially in treating neovascular age-related macular degeneration (wet AMD).
Expert retinal specialists, including Dr. David M. Brown, Dr. Glenn C. Yiu, and Dr. Victor Chong, will share their real-world experiences and insights. The webinar will discuss the current and future applications of Clearside's suprachoroidal delivery platform, including potential pipeline expansion.
The webinar will conclude with a live Q&A session. The live and archived webcast can be accessed on Clearside's website under the Investors section.
Clearside Biomedical (Nasdaq: CLSD) showcased its leadership in suprachoroidal delivery at the Clinical Trials at the Summit (CTS) Meeting on June 8, 2024. The presentations highlighted the broad application of suprachoroidal injections in treating retinal diseases, noting the promising safety and efficacy of their SCS Microinjector®. Dr. Victor Chong emphasized the potential of their FDA-approved product and the forthcoming CLS-AX data for wet AMD. Key studies presented included real-world data on XIPERE®, displaying 75% durability over six months, and updates on the ongoing ODYSSEY trial for CLS-AX with topline data expected in Q3 2024. Partner organizations presented data on their investigational therapies using Clearside's delivery platform for various ophthalmic conditions.
Clearside Biomedical announced that the journal RETINA has published new consensus guidelines for drug delivery via suprachoroidal space (SCS) injection. These guidelines, co-authored by 16 retinal physicians, detail best practices for SCS injection, including patient preparation, injection techniques, and post-injection care. This publication supports the use of Clearside's SCS Microinjector, which is already FDA-approved for uveitic macular edema and used in six ongoing clinical trials for various retinal diseases. Clearside's President, George Lasezkay, and Chief Medical Officer, Victor Chong, emphasized the clinical acceptance and adoption of their delivery platform.
Clearside Biomedical, Inc. (Nasdaq: CLSD) reported Q1 2024 financial results, focusing on the Phase 2b ODYSSEY Trial in Wet AMD with data expected in Q3 2024. The company aims to revolutionize eye therapy delivery through the suprachoroidal space. Management team strengthened with key additions like new Chief Medical Officer and Board member. Revenue increased, highlighting the successful completion of a direct offering, and positive data presentations on suprachoroidal drug delivery.
FAQ
What is the current stock price of Clearside Biomedical (CLSD)?
What is the market cap of Clearside Biomedical (CLSD)?
What does Clearside Biomedical, Inc. specialize in?
Where is Clearside Biomedical, Inc. located?
What is the SCS Microinjector®?
How does Clearside Biomedical's technology benefit patients?
What recent achievements has Clearside Biomedical reported?
Who can be contacted for investor and media inquiries?
What kind of presentations feature Clearside's technology?
What diseases is Clearside Biomedical targeting with their therapies?
Is Clearside Biomedical's procedure surgical?
What is the significance of Clearside's technology in ophthalmology?
